James M. Scheiman, MD
James M. Scheiman joined the UVA Division of Gastroenterology & Hepatology as chief in October 2017. A distinguished member of the University of Michigan’s Division of Gastroenterology for more than 30 years, Dr. Scheiman served as director of its Advanced Endoscopy Training Program and established the first endoscopic ultrasound program in the State of Michigan. It has since become nationally recognized for its productivity in clinical care and research.
Dr. Scheiman helped create the U-M’s Multidisciplinary Pancreatic Cancer Destination Program, coordinating care and conducting research focused on the early diagnosis of pancreatic cancer. An authority on the diagnosis and management of pancreatic cystic lesions, he spearheaded a definitive review on the topic commissioned by the American Gastroenterological Association that serves as the foundation for current clinical guidelines. His research on preventing the adverse effects of aspirin/NSAIDs on the GI tract has defined the current approach to management of this as well as other acid-related disorders. His team firmly established the ability of indomethacin to reduce the risk of post-ERCP pancreatitis; this groundbreaking study has defined the current standard and prevented this serious and deadly complication for countless patients all over the world. A key focus of his work has studied the cost-effective application of these new diagnostic approaches and therapies. Dr. Scheiman is the author of more than 250 original scientific publications and book chapters.
Dr. Scheiman received his BS and MD from the University of Michigan, and completed his internship, residency, and fellowship at the University of Michigan Affiliated Hospitals in Ann Arbor.